Rate of augmentation and risk factors with long-term follow-up in Japanese patients with restless legs syndrome
- 55 Downloads
Preventing augmentation is the critical clinical issue for RLS treatment. As for augmentation in Asian RLS patients, there have been only four studies and the follow-up durations of these studies were not long. We investigated Japanese RLS patients with longer duration of treatment in a clinical setting.
This study is a retrospective assessment of 42 RLS patients with follow-up durations of longer than 18 months (78.4 ± 29.2, range 19–139) at two urban sleep centers in Osaka, Japan from May 2004 to April 2014.
The mean age of first visit was 63.5 ± 14.1 years old and the estimated age of RLS onset was 47.9 ± 16.5 years old. Twenty-eight out of 42 patients were female. At initial evaluation, the mean International Restless Legs Scale score (IRLS score) was 22.0 ± 5.9. Thirty-one of 42 had already visited other clinics before coming to our sleep centers, and the number of clinics visited was 1.3 ± 0.6. Augmentation developed in two patients (4.8%), and the dosage of dopamine equivalent in patients with and without augmentation was 12.5 and 18.8 mg vs. 15.8 ± 17.7 mg. In the two RLS patients with augmentation, ferritin was 113.1 and 114.1 ng/mL, respectively, and the number of clinics before coming to our sleep centers was both three.
The augmentation rate of Japanese RLS patients from our study is low compared with previous Western and Asian studies. It might be attributable to racial difference, lower dosage of dopaminergic treatment, and the level of ferritin.
KeywordsAugmentation Dopaminergic treatment Ferritin Iron Restless legs syndrome (RLS)
The authors thank Drs. Takuya Oguri and Hanako Sugiyama who were in charge of the patients from 2006 to 2010 in Kansai Electric Power Hospital.
Conflict of interest
The authors declare that they have no conflicts of interest.
- 1.Winkelman JW, Armstrong MJ, Allen RP, Chaudhuri KR, Ondo WG, Trenkwalder C, Zee PC, Gronseth GS, Gloss D, Zesiewicz T (2016) Practice guideline summary: treatment of restless legs syndrome in adults: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 87(24):2585–2593CrossRefPubMedPubMedCentralGoogle Scholar
- 2.García-Borreguero D, Silber MH, Winkelman JW, Högl B, Bainbridge J, Buchfuhrer M, Hadjigeorgiou G, Inoue Y, Manconi M, Oertel W, Ondo W, Winkelmann J, Allen RP (2016) Guidelines for the first-line treatment of restless legs syndrome/Willis–Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med 21:1–11CrossRefPubMedGoogle Scholar
- 3.García-Borreguero D, Allen RP, Kohnen R, Högl B, Trenkwalder C, Oertel W, Hening WA, Paulus W, Rye D, Walters A, Winkelmann J, on behalf of the International Restless Legs Syndrome Study Group (IRLSSG) (2007) Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine—International Restless Legs Syndrome Study Group Consensus Conference at the Max Planck Institute. Sleep Med 8(5):520–530CrossRefPubMedGoogle Scholar
- 15.Allen RP, Picchietti DL, García-Borreguero D, Ondo WG, Walters AS, Winkelman JW, Zuccconi M, Ferri R, Trenkwalder C, Lee HB, on behalf of the International Restless Legs Study Group (2014) Restless legs syndrome/Willis–Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria—history, rationale, description, and significance. Sleep Med 15(8):860–873CrossRefPubMedGoogle Scholar
- 19.Trenkwalder C, Beneš H, Grote L, Happe S, Högl B, Mathis J, Saletu-Zyhlarz GM, Kohnen R, on behalf of the CALDIR study group (2007) Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial. Mov Disord 22(5):696–703CrossRefPubMedGoogle Scholar
- 20.García-Borreguero D, Ferini-Strambi L, Kohnen R (2008) Augmentation in the therapy of restless legs syndrome with transdermal rotigotine: a retrospective systematic analysis of two large double-blind 6-month trials. Eur J Neurol 15(Suppl.3):110Google Scholar
- 22.Trenkwalder C, Beneš H, Poewe W, Oertel WH, García-Borreguero D, Al W, Ferini-Strambi L, Montagna P, Odin P, Stiasny-Kolster K, Högl B, Chaudhuri KR, Partinen M, Schollmayer E, Kohnen R, for the SP 790 Study Group (2008) Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 7(7):595–604CrossRefPubMedGoogle Scholar
- 25.Högl B, García-Borreguero D, Kohnen R, Ferini-Strambi L, Hadjigeorgiou G, Hornyak M, Weerd A, Happe S, Stiasny-Kolster K, Gschliesser V, Egatz R, Frauscher B, Benes H, Trenkwalder C, Hening WA, Allen RP (2010) Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. J Neurol 257(2):230–237CrossRefPubMedGoogle Scholar
- 27.Beneš H, García-Borreguero D, Allen RP (2009) Augmentation in long-term therapy of the restless legs syndrome with transdermal rotigotine—a retrospective systematic analysis of two large open-label 1-year trials. Mov Disord 24:S438Google Scholar
- 30.García-Borreguero D, Högl B, Ferini-Strambi L, Winkelman J, Hill-Zabala C, Asgharian A, Allen RP (2012) Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks. Mov Disord 27(2):277–283CrossRefPubMedGoogle Scholar
- 31.García-Borreguero D, Kohnen R, Högl B, Ferini-Strambi L, Hadjigeorgiou GM, Hornyak M, Weerd A, Happe S, Stiasny-Kolster K, Gschliesser V, Egatz R, Cabrero B, Frauscher B, Trenkwalder C, Hening WA, Allen RP (2007) Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome. Sleep Med 8(5):455–463CrossRefPubMedGoogle Scholar
- 32.Oertel W, Trenkwalder C, Beneš H, Ferini-Strambi L, Högl B, Poewe W, Stiasny-Kolster K, Fichtner A, Schollmayer E, Kohnen R, García-Borreguero D, on behalf of the SP710 study group (2011) Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol 10(8):710–720CrossRefPubMedGoogle Scholar